Getinge Group: Correction: Getinge Announces Preliminary Results for Third Quarter 2013

  Getinge Group: Correction: Getinge Announces Preliminary Results for Third
  Quarter 2013

Business Wire

GETINGE, Sweden -- October 8, 2013

Regulatory News:

Getinge (STO:GETIB):

Getinge’s consolidated profit before tax for the third quarter 2013 is
expected to amount to 560-570 MSEK, which materially deviates from the
expectations indicated by the market consensus estimate.

The weaker earnings statement is primarily attributable to the following
factors:

- unfavorable product mix within the Critical Care division

- time delay in cost synergies related to the TSS acquisition

- the US Medical Device Tax and negative exchange-rate effects

For the full year, the organic volume growth is still expected to exceed last
year and amount to approximately 3-4 %. Profit before tax for the full year is
estimated to total at 3000 – 3200 MSEK including restructuring expenses and
other nonrecurring expenses.

This announcement will be followed by a conference call at 10.00 AM CET today,
hosted by Johan Malmquist, CEO Getinge Group and Ulf Grunander, CFO Getinge
Group.

Getinge will issue its full Q3 report for 2013 on October 15th at 1:00 PM CET.

Conference Call

To participate, please call:

Sweden: +46 (0)8 5065 3938

UK: +44 (0)20 3427 1905

Passcode: 7592961

Agenda

09.45 Call the conference number

10.00 Introduction

10.10 Q&A

11.00 End of conference

A recorded version of the conference will be accessible for five working days
at the following number:

Sweden: +46 (0)8 5051 3897

UK: +44 (0)20 3427 0598

US: +1347366 9565

Passcode: 7592961

GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and
life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

This information was brought to you by Cision http://news.cision.com

Contact:

Getinge Group
Johan Malmquist, CEO
Phone: +46 10 335 55 33
Email: johan.malmquist@getinge.com
or
Ulf Grunander, CFO
Phone: +46 10 335 55 80
Email: ulf.grunander@getinge.com
 
Press spacebar to pause and continue. Press esc to stop.